Reforms to the U.S. drug pricing environment are required, but to improve patients’ health outcomes, reforms must be grounded in a comprehensive understanding of the current drug pricing system. Otherwise, policymakers will make things worse, not better. An important piece by ACSH advisor Dr. Robert Popovian and Wayne Winegarden, Ph.D.
It's common practice for your pharmacy to substitute a generic version of a drug for its brand counterpart. But another cost-saving policy is being considered: substituting an entirely different drug from the same class as what was prescribed. This is a terrible idea, as Dr. Robert Popovian explains.